By Peter Griffin 21/08/2015


“Do you ever feel tired during the day? Do you suffer from mild headaches?” The questions were coming thick and fast from Gabi Arad, of Israeli medical device maker Itamar, which is based in the ancient Roman town of Caeserea, halfway between Tel Aviv and Haifa.

The previous night I’d worn to bed Itamar’s US$5,000 WatchPAT device, a bulky watch and sensors worn on my index finger and chest. I’d slipped into bed delicately, worried I’d rip the sensors out with my usual chaotic sleeping style. But I must have been subconsciously aware that I had test results to deliver – the WatchPAT revealed that I spent two-thirds of my five hours asleep in a supine position – lying flat on my back, the rest on my right side.

The test also revealed that I’m a bit of a snorer for 30 per cent of the time I was asleep I was snoring away, peaking for a brief moment at 70 decibels.

All of that was quite entertaining, but the purpose of Itamar’s device is deadly serious. It is designed to accurately test for sleep apnoea, a potentially serious sleep disorder in which breathing during sleep repeatedly stops and starts.

Wiring up with the WatchPAT
Wiring up with the WatchPAT

There are two main types of sleep apnoea:

– obstructive sleep apnoea (OSA) that occurs when the muscles in the back of the throat fail to keep the airway open, resulting in repeated breathing interruption.

– Central sleep apnoea, which is less common, more likely to afflict people with medical conditions and happens when the brain doesn’t send the right signals to muscles controlling breathing.

At its mildest, sleep apnoea can see a sleeper’s breathing pause for a few seconds, often followed by a snort as normal breathing resumes. But the worst case scenario is that it can shorten your life by putting stress on the body.

“It can slowly kill you,” says Arad who handles business development for Itamar for the Latin America and Asia Pacific regions. “And the economic costs of it are huge.”

He points to a study conducted jointly by consulting group McKinsey and Harvard University:

“We estimate the annual economic cost of moderate – severe OSA in the United States to be US$65 – $165B, which are greater than asthma, heart failure, stroke and hypertensive disease (US$20B to $80B)”

The actual cost of treating sleep apnoea is estimated at US$2 – $10 billion in the US. The rest of the cost comes in treating diseases and disorders that can result from it, such as cardiovascular disease, renal disease,diabetes and depression. The cost of accidents from people nodding off behind the wheel was estimated at US$35 billion a year, costing around 1,500 lives.

So sleep apnoea is a major problem.

Screen Shot 2015-08-21 at 1.32.09 PM
Itamar’s Gabi Arad with the WatchPAT

“Once you know you have sleep apnoea, it is very easy to treat,” says Arad. Typical treatments include an “oral appliance”, a sort of mouth guard that keeps the muscles working properly and the airway open. Another is continuous positive airway pressure (CPAP), a ventilator which applies mild air pressure to keep the airway open. Surgery is also a possibility. For mild sleep apnoea, Some doctors will simply encourage patients to loss weigh, exercise more and change their diet.

But a lot of sleep apnoea cases go undiagnosed. That’s partly due to the fact that the conventional accurate diagnosis for the sleeping disorder can involve a patient spending a night in a sleep clinic wired up to a machine checking vital signs. Even worse, up to 1 in 5 patients is misdiagnosed as not having sleep apnoea following a diagnostic study.

Increasingly however, the alternative is overnight oximitry – going home from your doctor with a portable device like the WatchPAT. The wrist watch is connected to a sensor that fits over the finger and which measures arterial volume changes in the fingertip. It also measures sleep time, including wake, light sleep, deep sleep and REM (rapid eye movement), the latter of which is associated with us dreaming.

Pulse rate and oxygen saturation is also measured, along with the aforementioned snoring events and body position.

A number of respiratory indices are based on the results:

pAHI (Apnoea-Hypopnoea Index):  Measures the number of apnoea and hypopnoea events per hour of sleep.

  • Normal: 0-4
  • Mild sleep apnea: 5-14
  • Moderate sleep apnea: 15-29
  • Severe sleep apnea: 30 or more

pRDI (Respiratory Disturbance Index): This is the AHI plus all other phenomena that can disrupt sleep – this can include things like snoring.

ODI (Oxygen Desaturation Index): This measures reductions in blood oxygen levels. Normal blood oxygen level (saturation) is usually 96 – 97%. Below that level and above 90% indicates mild oxygen desaturation, 80 – 89% is moderate and below 80% is severe.

“these test results are boring”

After wearing the WatchPAT for a relatively short night of sleep (5 hours and 47 minutes) I handed the device back in to Itamar and waited with trepidation for the results.

“These test results are boring,” says Arad finally, after a few questions probing for sleep apnoea symptoms like daytime drowsiness and headaches.

Screen Shot 2015-08-20 at 8.28.49 PM

Screen Shot 2015-08-20 at 8.29.17 PM

Phew! I’m normal.

My AHI was 4.2, my ODI was 1 and RDI was 14.9

Mean oxygen saturation was 95%

25% of my night’s sleep was in REM stage. Adults typically spend about 20 – 25% of their sleep in the REM stage while babies can spend up to 50% there.

Nothing out of the ordinary there.

A journalist colleague of mine who also underwent the test didn’t have as clear-cut results. Arad recommended he talk to his doctor about the results at his next check-up.

Such screening is relatively easy and inexpensive now, thanks to devices like the WatchPAT which Itamar sells all over the world.

But what about the Jawbone Up, the Fitbit and numerous other devices that claim to monitor how well you sleep? Are they going to put the WatchPAT out of the business?

“They claim to do it, but they just don’t do it,” says Arad. “The WatchPAT is a professional device validated in over 40 studies.”

About Itamar

publicly traded on the Tel Aviv Stock Exchange since 2007

Revenue: US$16.4 million in 2014

Market cap: US$83 million

Medical equipment maker Medtronic is a 20% shareholder

On the web: Itamar Medical

Peter Griffin visited Israel with the assistance of the Government of Israel